abstract |
The present invention provides a novel vaccine against epidemic parotitis composed of rMuV JL2 (recombinant epidemic parotitis virus Jeryl Lynn2 system) which is highly immunogenic. In addition, methods for developing immunogenic compositions are described in the present invention. The vaccine according to the invention is safe, cost-effective, very effective and stable and consistent in productivity. |